Cannabis Product and Services Reviews - Trusted leaves
Growing Elite Marijuana

research

Are cannabis shops targeting California’s Black, Latino and poor communities?

Unlicensed cannabis retailers are disproportionately setting up shop in California communities with higher percentages of Black and Latino residents, according to a new study by health experts from USC. That means, nearly four years after the state voted to license recreational cannabis businesses, residents of minority neighborhoods still have easier access to marijuana products that are highly potent, less likely to be tested for safety, don’t have child-safe packaging and are often cheaper than the highly regulated products found in licensed marijuana stores. Researchers say such access could worsen existing health disparities for minority and poor communities. Previous studies have shown that a similar pattern of locating disproportionate numbers of liquor and tobacco retailers in lowe...

Are cannabis shops targeting California’s Black, Latino and poor communities?

Unlicensed cannabis retailers are disproportionately setting up shop in California communities with higher percentages of Black and Latino residents, according to a new study by health experts from USC. That means, nearly four years after the state voted to license recreational cannabis businesses, residents of minority neighborhoods still have easier access to marijuana products that are highly potent, less likely to be tested for safety, don’t have child-safe packaging and are often cheaper than the highly regulated products found in licensed marijuana stores. Researchers say such access could worsen existing health disparities for minority and poor communities. Previous studies have shown that a similar pattern of locating disproportionate numbers of liquor and tobacco retailers in lowe...

Colorado’s first licensed cannabis R&D firm to study marijuana’s effect on Alzheimer’s disease

A Denver-based company hopes to be the state’s first to study the effects of marijuana on Alzheimer’s disease, thanks to a newly available research and development license in the city. MedPharm Holdings plans to apply for a Denver marijuana R&D license to test delta-9 tetrahydrocannabinol (THC), cannabidiol (CBD) and other cannabinoids’ effects on Alzheimer’s and dementia patients. According to the Alzheimer’s Association, 5.8 million Americans have the disease, a degenerative brain disorder that affects a person’s memory and thinking skills. While there are drugs that help ease symptoms, they do not change the course of the disease. Read the rest of this story on DenverPost.com.